

CURRICULUM VITAE

NAME: Purvi K. Mehra, MD

POSITION TITLE: Principle Investigator

CORPORATE ADDRESS:

eStudySite
292 Euclid Avenue #225
San Diego CA 92114

CONTACT INFORMATION:

Telephone: (619)995-5246
Fax: (619)656-9761
e-Mail: PMehra@estudysite.com

RESEARCH SITE ADDRESS #1

752 Medical Center Court #105
Chula Vista, CA 91911

RESEARCH SITE ADDRESS #2

655 Euclid Ave. #305
National City, CA 91950

PROFESSIONAL LICENSURE: Medical License #A77567, 2002

BOARD CERTIFICATIONS (if applicable): Internal Medicine
Allergy/Immunology

EDUCATION/TRAINING:

(Include baccalaureate or other initial professional education such as nursing, postdoctoral training, GCP training.)

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Scripps Clinic La Jolla, CA	N/A	2003-2005	Allergy/Immunology Fellowship Program
Scripps Mercy Hospital San Diego, CA	N/A	2000-2003	Internal Medicine Residency Training Program
University of Texas Health Science Center San Antonio, TX	M.D.	1996-2000	Medicine
University of Texas Austin, TX	B.A.	1992-1996	Psychology

HOSPITAL AFFILIATIONS

8/2005- Paradise Valley Hospital
Current 2400 East 4th St.
National City, CA 91950

12/2005- Sharp Chula Vista Medical Center
current 751 Medical Center Court #105
Chula Vista, CA 91911

POSITIONS AND EMPLOYMENT

2005- Investigator, eStudySite, San Diego, CA
current
2004-2005 Sub-Investigator, Profil Institute for Clinical Research, Chula Vista, CA
2004-2005 Staff Internal Medicine, Skilled nursing facility, Scripps Clinic
La Jolla, CA
2002-2004 Supervising Physician, Institute for Health Maintenance, San Diego, CA

PUBLICATIONS:

Dyspnea, wheezing, and airways obstruction: Is it asthma? Mehra, Purvi K.; Woessner, Katharine M. Allergy and Asthma Proceedings. Volume 26, Number 4, July-August 2005, pp. 319-322(4)

Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease. Stevenson DD, Mehra PK, White AA, Gupta S, Woessner KM, Simon RA. J Allergy Clin Immunol 2005 Oct;116(4):755-60.

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:

- 6/2003-
current San Diego Allergy Society
 American Academy of Allergy, Asthma, and Immunology
- 8/2003-
current American College of Allergy, Asthma, and Immunology
- 8/2003-
current

RESEARCH EXPERIENCE

Sub-Investigator- Paradise Valley Hospital, National City, CA conducted for Basilea Pharmaceutical through ICON:

- Complicated skin and skin structure infections, Protocol #BAP00154, 2005

Sub-Investigator - Paradise Valley Hospital, National City, CA conducted for Theravance Inc. through Duke Clinical Research Institute:

- Complicated gram-positive skin and skin structure infections, Protocol #I6424-202a, 2003
- Uncomplicated Staphylococcus aureus bacteremia, Protocol #I6424-203a, 2003
- Complicated gram-positive skin and skin structure infections, Protocol #I6424-202b, 2004
- Hospital-acquired pneumonia, Protocol #0015, 2005

Sub- Investigator - Paradise Valley Hospital, National City, CA conducted for Theravance Inc. through Covance:

- Complicated gram-positive skin and skin structure infections, Protocol #0017, 2004

Sub- Investigator – Paradise Valley Hospital, National City, CA conducted for Aventis Pharmaceuticals Inc., through Covance Periapproval Services, Inc.:

- VTE – Venous Thromboembolism prophylaxis, Protocol #XRP4563C/3501, 2002

- VTE/stroke, Protocol XRP4563H/3501, 2004

Sub- Investigator – Paradise Valley Hospital, National City, CA conducted for Versicor Inc., through Versicor (formerly Barton & Polansky Associates Inc.):

- Uncomplicated skin and soft tissue infection, Protocol #VER001-8, 2003
- Complicated skin and soft tissue infection, Protocol #VER001-9, 2003

Sub-Investigator – Paradise Valley Hospital, National City, CA conducted for Ortho-McNeil Pharmaceutical, Inc. through Advanced Biologics:

- UTI/pyelonephritis, Protocol #CAPSS-349, 2005

Sub-Investigator – Sharp Chula Vista Medical Center, CA conducted for Theravance Inc. through Duke Clinical Research Institute:

- Uncomplicated Staphylococcus aureus bacteremia, Protocol #I6424-203a, 2006
- Hospital-acquired pneumonia, Protocol #0015, 2005

Sub-Investigator – Sharp Chula Vista Medical Center, CA conducted for Theravance Inc. through Covance:

- Complicated gram positive skin and skin structure infections, Protocol #0017, 2005

Sub-Investigator – Sharp Chula Vista Medical Center, CA conducted for Cerexa through US Micron:

- Complicated skin and skin structure infections, Protocol #P903-03, 2006

Sub-Investigator – Sharp Chula Vista Medical Center, CA conducted for Johnson & Johnson, through ICON:

- Complicated skin and skin structure infections, Protocol #BAP00414, 2006

Study Summary March 2004 – August 2005

Study Phase	Therapeutic area	Study Population	Compound Class	Duration
Phase 1, FTIH	Obesity	Healthy	Peptide	42 hour inpt, 12 weeks
Phase 1, FTIP	Obesity	Healthy obese	Peptide	42 hour inpt, 12 weeks
Phase 2	Diabetes	Type 2, insulin+orals	Peptide	24 hour inpt x2; 24 weeks
Phase 1, Clamp	Diabetes	Type 2, insulin	Basal insulin	24 hour inpt x6; 8 weeks
Phase 2	Obesity	Healthy obese	Peptide	8 days inpt; 6 weeks
Phase 1, FTIH	Diabetes	Healthy	Novel oral hypoglycemic	4 days inpt x4; 16 weeks

Phase 1, FTIP	Diabetes	Type 2, diet & exer. or single agent	Novel oral hypoglycemic	4 days inpt x 3; 12 weeks
Phase 1, Clamp/device	Diabetes	Type 2, insulin +/- orals	Inhalable insulin	12 hour inpt x2; 4 weeks
Phase 1, Clamp/device	Diabetes	Type 2, insulin +/- orals	Inhalable insulin	12 hour inpt x 1; 2 weeks
Phase 1, FTIM	Diabetes	Type 2, diet & exer. or single agent	Novel oral hypoglycemic	40 hour inpt x4; 6 weeks
Phase 1, Pilot	Diabetes	Healthy normal	Oral vs subcu insulin	8 hours x 5; 6 weeks
Phase 1	Diabetes	Healthy normal	Oral vs Subcu insulin	8 hours x 4; 6 weeks
Phase 1, Pilot/ POC; Hyper/Hypo clamp	Diabetes	Healthy Normal; Type 1 diabetes; Type 2 diabetes	Glucose sensing device	12 hours x 1; 2 weeks
Phase 2; POC	Diabetes	Type 2, single agent	DPP IV inhib.	6 month outpt
Phase 1; FTIM Clamp	Diabetes	Healthy Normal	Subcut. Insulin	8 hours x 4; 6 weeks
Phase 2; POC	Obesity	Healthy obese	Peptide	6 months outpt
Phase 1; Pilot	Diabetes	Type 2, single agent	Oral PPAR	48 hour inpt x 3; 12 weeks

FTIH = First time in humans

FTIP = First time in patients

POC = Proof of concept

Sponsor list:

Merck, Kos, GSK, Novo Nordisk, Amylin, Roche, Lilly, Mannkind, Bidel, Novartis, Syrex